Clinical trials: Cardio-Renal Syndrome
Cardio-Renal Syndrome
Contrast-induced Nephropathy: Incidence,Risk Factors,Effective Prevention and Management Method
This review article have included about ten thousand patients undergoing percutaneous coronary intervention (PCI), aim to identify the incidence of CIN in actual, find some new risk factors and the protecting methods for these…
- Trial name
- NCT02664246
- Testing
- percutaneous coronary intervention
- Volunteers
- 10,000 people
- Sponsor
- Chinese PLA General Hospital
Cardiorenal Syndrome
Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure
Although the traditional determinant of renal dysfunction in heart failure was suggested as decreased cardiac output and renal hypo perfusion, recent studies have demonstrated the association of persistent systemic venous…
- Trial name
- NCT02372292
- Testing
- intravenous furosemide
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Ankara University
Heart Failure, Diabetic Kidney Disease
Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study
This study evaluates the safety of finerenone compared with alternate-day spironolactone in patients with heart failure and diabetic kidney disease at increased risk of hyperkalemia.
- Conditions
- Heart Failure, Diabetic Kidney Disease, Hyperkalemia
- Trial name
- SAFE-K (NCT07523867)
- Testing
- Finerenone, Spironolactone (drug)
- Volunteers
- 60 people
- Sponsor
- Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Heart Failure, Renal Insufficiency
Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients With Cardio Renal Syndrome With Severe Renal Impairment
Renal failure is present in 40% of heart failure patients, and is one of the main comorbidities of heart failure. Follow-up with pulmonary artery pressure (PAP) monitoring has shown a reduction in mortality and frequency of…
- Trial name
- CARDIOMEMS (NCT05428631)
- Testing
- Implantation of the CARDIOMEMS™ HF device
- Where
- 2 sites in France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cardiovascular Diseases (CVD), Chronic Kidney Disease
Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome
This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome…
- Conditions
- Cardiovascular Diseases (CVD), Chronic Kidney Disease, Metabolic Diseases, Cardiovascular-kidney-metabolic Syndrome
- Trial name
- CKM-LCBP (NCT07547098)
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Congestive Heart Failure
Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention
The effect of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on the parameters of renal function in acute decompensation of chronic heart failure (ADHF) compared to standard therapy will be analyzed.
- Trial name
- NCT04778787
- Testing
- Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
- Where
- 2 sites in Russia
- Volunteers
- 370 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Among adult individuals with type 2 diabetes mellitus and at risk for heart failure with impaired relaxation of the heart mildly reduced kidney filtration function (Type 4 cardiorenal syndrome) this trial will evaluate the…
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
- Trial name
- NCT02251431
- Testing
- BYDUREON
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Baylor Research Institute
Heart Failure and Chronic Kidney Disease Post-ICU
Dapagliflozin for Cardio-renal Protection After ICU Discharge
Several millions of patients are admitted to ICUs in Europe or USA each year. We and others, have shown that patients discharged from intensive care units (ICU) have a high incidence of cardiovascular and/or renal events and high…
- Trial name
- DAPA-ICU (NCT07025629)
- Testing
- Dapagliflozin 10 MG Oral Tablet [Farxiga]
- Where
- 2 sites in France
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiorenal Syndrome, Acute Kidney Injury
Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1
During cardiorenal syndrome type 1 (CRS1) vascular congestion is the major contributor to worsening renal function, but promoting decongestion with routine clinical evaluation is ineffective in some patients.
- Conditions
- Cardiorenal Syndrome, Acute Kidney Injury, Decompensated Heart Failure, Fluid Overload
- Trial name
- NCT05927285
- Testing
- Vexus, Control group
- Where
- Mexico
- Volunteers
- 140 people
- Sponsor
- Hospital Civil de Guadalajara
Empagliflozin in Cardiorenal Syndrome Type 1
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.
- Trial name
- TREAT-CRS (NCT06030843)
- Testing
- Empagliflozin 10 MG
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Chulalongkorn University
Chronic Heart Failure, Cardio-Renal Syndrome
Renal Denervation in Patients With Chronic Heart Failure
The purpose of the trial is to investigate the safety and effectiveness of renal denervation for the treatment of chronic heart failure (CHF).
- Trial name
- NCT02085668
- Testing
- Renal denervation (Symplicity™)
- Where
- 11 sites in Austria, Germany and 2 more
- Sponsor
- University Hospital, Saarland
Heart Failure, Systolic, Heart Failure, Diastolic
Implementation of Telerehabilitation In Support of HOme-based Physical Exercise for Heart Failure
ITISHOPE4HF is a randomized controlled trial of telerehabilitation in a heart failure population. The goal is to evaluate if a home-based telerehabilitation project can increase physical activity in heart failure patients.
- Conditions
- Heart Failure, Systolic, Heart Failure, Diastolic, Chronic Kidney Diseases, Cardiorenal Syndrome
- Trial name
- ITISHOPE4HF (NCT03183323)
- Testing
- Telerehabilitation
- Where
- Norway
- Volunteers
- 61 people
- Sponsor
- Helse Nord-Trøndelag HF
Cardio-Renal Syndrome
Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy
Patients at moderate and high risk for contrast induced nephropathy (CIN) should receive sufficient hydration before application of contrast to prevent CIN, but hydration could obviously increase the preload for congestive heart…
- Trial name
- NCT02405377
- Testing
- hydration, Visipaque, 0.9% sodium chloride fluid administration
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Chinese PLA General Hospital
Cardiorenal Syndrome
Dobutamaine Versus Milrinone in Cardiorenal Syndrome
Heart failure is recognized as one of the most common indications for hospitalization amongst adults aged >65 years in United States with estimated Medicare cost to be 17 billion or more.
- Trial name
- DOMICAS (NCT02644057)
- Testing
- Milrinone, Dobutamine
- Where
- United States
- Sponsor
- Maimonides Medical Center
Acute Decompensated Heart Failure (ADHF)
Efficacy and Safety of Compression Boots in Patients With Acute Decompensated Heart Failure.
The aim of this clinical trial is to investigate whether pulsatile compression therapy can support heart and kidney function in patients admitted with acute heart failure and fluid accumulation in the legs.
- Trial name
- COMPLEX (NCT07377019)
- Testing
- Pulsatile Compression Boots (PCB)
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Odense University Hospital
Cardio-renal Syndrome
Ultrafiltration Versus Medical Therapies in the Management of the Cardio Renal Syndrome
Type 2 cardio renal syndrome is defined by the occurrence or the exacerbation of a kidney failure induced by a chronic heart failure.
- Trial name
- UF-CARE (NCT02846337)
- Testing
- ULTRAFILTRATION, ENHANCED MEDICAL TREATMENT
- Where
- France
- Volunteers
- 108 people
- Sponsor
- Hospices Civils de Lyon
Heart Failure
Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure
This study has two primary objectives: 1. To compare combination therapy with acetazolamide and low-dose loop diuretics versus high-dose loop diuretics (standard of care) in patients with acute decompensated heart failure at high…
- Trial name
- DIURESIS-CHF (NCT01973335)
- Testing
- Combination therapy with acetazolamide and low-dose loop diuretics, High-dose loop diuretics, Upfront therapy with oral spironolactone
- Where
- 2 sites in Belgium
- Volunteers
- 34 people
- Sponsor
- Hasselt University
Cardiorenal Syndrome, Heart Failure
Venous Ultrasound Guided Organ Decongestion in Patients Hospitalized with Acute Decompensated Heart Failure
The purpose of this study is to assess the feasibility, safety and effectiveness of VExUS guided organ decongestion compared to standard of care in patients hospitalized with acute decompensated heart failue (ADHF).
- Conditions
- Cardiorenal Syndrome, Heart Failure, Acute Kidney Injury, Acute Decompensated Heart Failure
- Trial name
- VExOUS-ADHF (NCT06714409)
- Testing
- VExUS guided decongestion
- Where
- Norway
- Volunteers
- 180 people
- Sponsor
- Oslo University Hospital
Heart Failure, Renal Insufficiency
Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure
The purpose of this study is to evaluate the effect of levosimendan infusion, in addition to standard therapy,on renal function in patients with Acute Heart Failure,compared with standard therapy alone.
- Trial name
- NCT00527059
- Testing
- Levosimendan in addition to standard therapy, spironolactone, beta-blockers,ecc
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- University of Roma La Sapienza
Acute Decompensated Heart Failure
REWORD-HF REverse WOrsening Renal Function in Decompensated Heart Failure
The purpose of this study is to determine whether in patients with acute decompensated congestive heart failure and the cardiorenal syndrome, i.e.
- Trial name
- REWORD-HF (NCT01140399)
- Testing
- Furosemide or Furosemide and Dopamine, Ultrafiltration
- Where
- 16 sites in Italy
- Volunteers
- 10 people
- Sponsor
- Niguarda Hospital